Aims/hypothesis Impaired
Results Treatment with glucose increased gene expression and transcriptional activity for Sepp1 in H4IIEC hepatocytes. Physiological concentrations of SeP inhibited VEGFstimulated cell proliferation, tubule formation and migration in HUVECs. SeP suppressed VEGF-induced reactive oxygen species (ROS) generation and phosphorylation of VEGF receptor 2 (VEGFR2) and extracellular signal-regulated kinase 1/2 (ERK1/2) in HUVECs. Wound closure was impaired in the mice overexpressing Sepp1, whereas it was improved in SeP −/− mice. SeP +/− mice showed an increase in blood flow recovery and vascular endothelial cells after hindlimb ischaemia. Conclusions/interpretation The hepatokine SeP may be a novel therapeutic target for impaired angiogenesis in type 2 diabetes.
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Introduction
Type 2 diabetes is a chronic hyperglycaemic condition that causes various vascular complications, including damage to: small blood vessels, resulting in retinopathy, nephropathy and neuropathy; and large blood vessels, resulting in cardiovascular diseases. Earlier improved glycaemic control is associated with reduced risk for cardiovascular disease in people with type 2 diabetes [1] . However, more recent clinical trials have indicated that strict glycaemic control does not necessarily prevent vascular complications [2] . Hence, beyond glycaemic control, novel therapies to directly treat vascular disease are needed to improve the prognosis of people with type 2 diabetes.
Angiogenesis is a physiological process involving the growth of new blood vessels from pre-existing vascular structures and the subsequent formation of a vascular network. A number of abnormalities associated with angiogenesis have been observed in people with type 2 diabetes [3] , and impaired angiogenesis is linked to the development of various vascular complications in diabetes mellitus. Compared with control individuals without diabetes, people with type 2 diabetes show poor development of coronary collateral vessels on coronary angiography [4] . Moreover, a previous study using autopsied hearts reported that people with diabetes have significantly lower capillary densities in areas of myocardial infarction [5] . These reports suggest that the angiogenic response to infarction and/or ischaemia is inhibited at the levels of capillaries and small arterioles in type 2 diabetes. Inadequate vascular formation could attenuate perfusion recovery in response to ischaemia, thereby partially accounting for the poor clinical outcomes in type 2 diabetic patients with coronary heart disease or peripheral artery disease [6, 7] . In addition, insufficient angiogenesis is involved in abnormal wound healing and the development of diabetic skin ulcers [8] .
Vascular endothelial growth factor (VEGF) is a major mediator of angiogenesis under physiological and pathophysiological conditions. VEGF binds and phosphorylates its receptors, leading to the activation of a variety of signalling cascades such as the mitogen-activated protein kinase (MAPK) and Akt cascades. Angiogenic gene therapy using plasmids encoding VEGF has been attempted in patients with coronary or peripheral artery diseases [9] . However, diabetes mellitus people often show a poor response to therapeutic angiogenesis [10] . Therefore, VEGF resistance, a defect of VEGF-related signal transduction, has been postulated as a molecular basis for the dysregulated angiogenesis in diabetes mellitus [3, 11] . The molecular mechanisms underlying VEGF resistance in diabetes mellitus are not fully understood.
Selenoprotein P (SeP, encoded by SEPP1 in humans and Sepp1 in mice) is a secretory protein produced primarily in the liver [12, 13] . It contains ten selenocysteine residues and functions as a selenium supply protein [14] . We have previously reported that levels of serum SeP and hepatic gene expression of SEPP1 are elevated in type 2 diabetes [15] . More recently, Yang et al have reported that serum levels of SeP are increased in people with impaired glucose tolerance [16] . SeP impairs insulin signal transduction and induces dysregulation of glucose metabolism in skeletal muscle and liver, indicating that SeP functions as a type 2 diabetesassociated hepatokine that causes insulin resistance and hyperglycaemia [15] . SeP has heparin-binding properties [17] and is associated with endothelial cells in rat tissues [18] , suggesting that SeP exerts some actions on vascular endothelial cells. A previous study using in vitro techniques reported that SeP has an antioxidative action in vascular endothelial cells [19] . Nevertheless, it is unknown whether SeP plays a role in the angiogenic response.
We speculated that the liver-derived secretory protein SeP contributes to angiogenesis-associated vascular complications in type 2 diabetes by acting directly on vascular endothelial cells. In the current study, we investigated the effects of SeP on angiogenesis in normal conditions, independently of diabetes, using purified SeP protein and Sepp1-deficient mice without the induction of diabetes.
Methods
Cell culture HUVECs were cultured in HuMedia EG2 (Kurabo, Osaka, Japan). H4-II-E-C3 cells were cultured in 10% (vol./vol.) fetal bovine serum (FBS)/DMEM (Gibco, Carlsbad, CA, USA) as previously described [20] . All cellular experiments were approved by the Committee for Cellular Study at our Institute.
Animals The Sepp1-deleted mice were produced by homologous recombination with genomic DNA cloned from a Sv-129 P1 library [21] . All animal studies were approved by the Committee for Animal Studies at our Institute. See the electronic supplementary material (ESM) for further details.
Measurement of selenium Total selenium concentrations were determined using a modification of Watkinson's method [22, 23] . See the ESM for further details.
SEPP1 promoter assay The human SEPP1 promoter region was cloned to a luciferase reporter vector, and luciferase activities were measured using the dual luciferase assay system (Promega, Madison, WI, USA) [20] . See the ESM for further details.
Cell proliferation assay HUVECs were quantified using Cell Counting Kit-8 (Wako, Osaka, Japan). See the ESM for further details.
Migration assay HUVECs were seeded in the upper chamber of polycarbonate filters, and the number of cells migrating across the filter was counted. See the ESM for further details.
Cell tubule formation assay HUVECs were seeded on plates coated with ECMatrix gel. Endothelial tubule formation was photographed under a microscope. See the ESM for further details.
Matrigel plug implantation assay This assay was performed using a directed in vivo angiogenesis assay inhibition kit (Trevigen, Gaithersburg, MD, USA). See the ESM for further details.
Western blot analysis HUVECs were pretreated with SeP for 24 h. After 2 h of starvation, HUVECs were stimulated with VEGF for 15 min. See the ESM for further details.
RNA preparation and quantitative real-time Real-time PCR was performed on an ABI-Prism 7900HT (Applied Biosystems, Carlsbad, CA, USA). See the ESM for further details.
Reactive oxygen species generation Intracellular reactive oxygen species (ROS) levels were measured using 2′,7′-dichlorofluorescein diacetate (DCF) and quantified using a fluorescent plate reader (Fluoroskan Ascent FL, Yokohama, Japan). See the ESM for further details.
Purification of SeP SeP was purified from human plasma using conventional chromatographic methods [14, 24] . See the ESM for further details.
Preparation of human SEPP1 plasmids and overexpression of SeP in mice The human SEPP1 expression plasmids were provided by Kaketsuken (The Chemo-Sero-Therapeutic Research Institute, Tokyo, Japan). Plasmid was injected into the tail vein of mice. See the ESM for further details.
Measurement of serum human SeP in mice injected with human SEPP1 plasmid Serum levels of human SeP were measured by enzyme-linked immunosorbent assays using two monoclonal antibodies [15, 25] .
Mouse wound healing model Full-thickness wound was created, and the extent of wound closure was examined. See the ESM for further details.
Hindlimb ischaemia model Mice underwent ligation and segmental resection of the left femoral vessel [26] . See the ESM for further details.
Identification of CD31
+ vessels An antibody to CD31 was used for immunostaining. See the ESM for further details.
Calculations and statistical analysis All data were analysed using SPSS version 11.0 (Japanese Windows Edition; SPSS, www.ibm.com/software/analytics/spss/). See the ESM for further details.
Results
Glucose increases gene expression and transcriptional activity for SeP in cultured hepatocytes
To confirm the elevation of SeP in the livers of people and animal models with type 2 diabetes [15] , we examined the action of glucose on Sepp1 expression in H4-II-EC hepatocytes (Fig. 1 ). Sepp1 mRNA expression was significantly increased by 25 mmol/l glucose in a time-dependent manner (Fig. 1a) . Additionally, SEPP1 promoter activity as measured by luciferase activity was increased by 25 mmol/l glucose compared with mannitol (Fig. 1b) . These results are consistent with our previous findings showing that treatment with high glucose increases protein levels of SeP in mouse primary hepatocytes [15] . These results indicate that high concentrations of glucose increase the transcriptional activity of SeP genes in the cultured hepatocytes.
SeP impairs VEGF-induced angiogenesis in endothelial cells
To assess the direct action of the liver-derived secretory protein SeP on vascular endothelial cells, we treated HUVECs with purified human SeP protein. HUVECs were treated with 5 or 10 μg/ml purified human SeP protein, corresponding to serum levels of SeP in healthy individuals or people with type 2 diabetes [15] . In addition, we confirmed that levels of selenium were undetectable (less than 2.5 ng/ml) in all the culture media used for HUVECs. VEGF-induced proliferation of HUVECs was significantly suppressed by treatment with 10 μg/ml SeP (Fig. 2a) . Co-administration of buthionine sulfoximine (BSO), an inhibitor of glutathione synthesis, partly rescued the suppressive effect of SeP.
Next, we examined the effects of SeP on VEGF-induced migration in HUVECs. VEGF promoted the migration of HUVECs across polycarbonate filters. This migration was inhibited by the addition of SeP in a concentrationdependent manner (Fig. 2b, c) . In the absence of VEGF, treatment with SeP did not affect the migration of HUVECs, suggesting that SeP modulates VEGF-dependent migration of endothelial cells. We further examined the effects of SeP on tubule formation in HUVECs. HUVECs cultured on Matrigel containing VEGF showed morphological tubule formation, with a lumen surrounded by endothelial cells adhering to one another (Fig. 2d) . SeP inhibited tubule formation of HUVECs in a concentration-dependent manner (Fig. 2d-e) . These in vitro results indicate that SeP at physiological concentrations impairs VEGF-dependent angiogenesis of vascular endothelial cells.
SeP reduces VEGF-stimulated formation of new vessels in Matrigel
The role of SeP in angiogenesis in vivo was further determined by Matrigel plug implantation assay. Matrigel was mixed with VEGF in the presence or absence of SeP protein and the plugs were implanted into the dorsal subcutaneous tissue of mice. After 10 days, angiogenesis inside the Matrigel was quantified. SeP markedly inhibited VEGF-stimulated formation of new vessels in the Matrigel (Fig. 2f) . These results further indicate that SeP impairs angiogenesis in vivo.
SeP impairs VEGF signal transduction in endothelial cells Next, we determined whether SeP affects VEGF signal transduction in endothelial cells. Pretreatment with SeP impaired VEGF-stimulated phosphorylation of VEGF receptor (VEGFR)2 (Tyr1175) and extracellular signal-regulated kinase 1/2 (ERK1/2) (Thr202/Tyr204) in HUVECs (Fig. 3a, b) . Co-administration of BSO partially rescued the inhibitory effect of SeP on VEGF signalling (Fig. 3a, b) . The mRNA expression of VEGFR2 (also known as KDR) in HUVECs was unaffected by treatment with purified human SeP protein (Fig. 3c) . These results indicate that SeP at physiological concentrations impairs VEGF signal transduction in vascular endothelial cells.
SeP suppresses VEGF-induced acute generation of ROS in HUVECs To clarify the mechanism by which the antioxidative protein SeP impairs VEGF signalling, we assessed the action of SeP on the acute generation of ROS stimulated by VEGF. The VEGF-induced ROS burst is reported to be required for the subsequent VEGF signal transduction [27] . Stimulation with 50 ng/ml VEGF for 5 min significantly increased intracellular levels of ROS in HUVECs (Fig. 3d) . Pretreatment with SeP suppressed intracellular levels of ROS both with and without VEGF stimulation (Fig. 3d) . These results suggest that SeP-induced VEGF resistance is associated with a reduction in the ROS burst stimulated by VEGF.
SeP delays wound healing of skin in mice To clarify whether hepatic overexpression of SeP affects angiogenesis-related disorder in vivo, we used a hydrodynamic injection method to generate mice that overexpress human SEPP1 mRNA in the liver. Levels of SEPP1 gene expression in the liver and SeP protein in the blood were significantly elevated in these mice (Fig. 4a, b) , whereas serum levels of total selenium in wildtype and SeP-transgenic mice, which were 322.6 ng/ml and 331.0 ng/ml respectively, were not significantly different (Fig. 4c) . We created excisional wounds (10 mm) in the dorsal skin of the mice and quantified the rate of wound healing. Wound closure was significantly impaired in the mice overexpressing SEPP1 at 3, 5 and 7 days (Fig. 4d, e) . In contrast, Sepp1 −/− mice showed an improvement of the wound closure at 9 days compared with the wild-type animals (Fig. 4f, g ). These results indicate that the hepatokine SeP delays the wound healing of the skin in mice.
Sepp1-heterozygous-knockout mice show enhanced angiogenesis after hindlimb ischaemia To determine whether attenuation of SeP expression enhances angiogenesis in vivo, we generated hindlimb ischaemia in Sepp1 +/− mice. We previously reported that Sepp1-homozygous-knockout mice exhibit enhancement of insulin signalling in skeletal muscle, whereas Sepp1-heterozygous-knockout mice show marginal changes in insulin signalling [15] . Hence, we selected Sepp1-heterozygous-knockout mice in the present study to assess the direct actions of SeP on the vascular system, independent of insulin signalling. At 5 days after femoral artery ligation, Sepp1 +/− mice showed a significant increase in blood flow compared with wild-type mice (Fig. 5a ). This increase continued for 15 days after artery ligation (Fig. 5b) . Consistent with these findings, histological examination showed increased vessel density in the hindlimb musculature as determined by immunostaining with anti-CD31 antibody (Fig. 5c, d ).
Discussion
The present study indicates that the liver-derived secretory protein SeP impairs angiogenesis both in vitro and in vivo. SeP directly attenuates VEGF signal transduction in vascular endothelial cells, resulting in suppression of VEGF-induced cell proliferation, migration and tube formation. We reported previously that levels of both hepatic SEPP1 mRNA and serum SeP protein are elevated in type 2 diabetes [15] . Taken together with our previous report, the present study suggests that hepatic overproduction of SeP may contribute to the onset of impaired angiogenesis in type 2 diabetes (Fig. 6) . The attenuated VEGF signal transduction, VEGF resistance, has been postulated as the molecular mechanism underlying the dysregulation of angiogenesis in people with type 2 diabetes [3, 11] . Waltenberger et al reported that circulating monocytes show attenuation of VEGF-induced chemotaxis in people with diabetes mellitus [28] and that VEGF-stimulated phosphorylation of downstream molecules is reduced in monocytes from patients with type 2 diabetes [29] . In addition, Sasso et al found impaired VEGF signalling in the myocardium of patients with type 2 diabetes and coronary mice (white circles) and control (black circles) (n=6-12). Data are mean ± SEM. *p<0.05, scale bars, 10 mm. WT, wild-type heart disease [30] , suggesting that diabetes induces VEGF resistance in not only monocytes but also other types of cells such as cardiomyocytes and endothelial cells. However, the molecular mechanisms by which VEGF resistance arises in diabetes mellitus have not been elucidated. The results of the present study suggest a novel molecular pathology of type 2 diabetes; elevation of circulating SeP induces VEGF resistance in vascular endothelial cells.
The liver is the production site of various secretory proteins. Recent work in our laboratory has indicated that genes encoding secretory proteins are abundantly expressed in the liver in type 2 diabetes [31] . Moreover, genes encoding angiogenic factors, fibrogenic factors and redox-associated factors are differentially expressed in the liver in type 2 diabetes, possibly contributing to the pathophysiology and clinical manifestations of this disease [32, 33] . The present study sheds light on a previously under-explored function of the liver; the liver may participate in the regulation of systemic angiogenesis by altering the production of angiogenesisassociated hepatokines such as SeP.
Our observation that SeP impairs angiogenic processes is noteworthy in the context of experimental data suggesting that SeP plays a role in the antioxidative defence system [13] . In fact, we have shown previously that SeP increases the activity of glutathione peroxidase 1 (GPX1), a representative antioxidative enzyme that requires selenium for its enzymatic action, in Jurkat E6-1 cells, a human T cell leukaemia cell line [14] . SeP-induced activation of GPX1 was also demonstrated in endothelial cells [19] . Accumulating evidence indicates that ROS stimulate the angiogenic response in order to initiate the tissue repair process in ischaemia-reperfusion lesions [34] . Among the growth factors involved in angiogenesis, VEGF plays a role in a ROS-dependent signal transduction system [27] . VEGF binding to VEGFR2 stimulates NADPH oxidase in endothelial cells, resulting in the acute generation of ROS such as hydrogen peroxide. This ROS burst oxidises and inactivates protein tyrosine phosphatases, which negatively regulate VEGF signalling and thereby promote VEGFR2 phosphorylation and the subsequent signalling cascade [27] .
In combination with these previous reports, the present data suggest that SeP induces VEGF resistance in endothelial cells by increasing GPX1 and subsequently suppressing the VEGFinduced ROS generation that is required for VEGF signal transduction. This speculation was supported by our findings that the co-administration of BSO, an inhibitor of glutathione synthesis, rescued the inhibitory effects of SeP on VEGF signalling and the subsequent VEGF responsiveness. The identification of SeP receptor(s) in endothelial cells would provide further insight into the molecular mechanism by which SeP impairs VEGF signal transduction.
VEGF signalling is known to play paradoxical roles in the pathogenesis of diabetic complications. Both enhancement and suppression of angiogenesis are observed in different tissues in diabetic conditions [35] . In contrast to hindlimb ischaemia or wound healing, advanced diabetic retinopathy is characterised by VEGF-induced abnormal neovascularisation in the retina. Current management for diabetic retinopathy includes anti-VEGF therapy along with blood glucose control [36] . In addition to retinopathy, growing evidence indicates that VEGF-related abnormal angiogenesis plays a major role in diabetic nephropathy [37] . Moreover, a recent report showed that pharmacological inhibition of VEGF-B improves glucose tolerance and insulin resistance in rodent models with type 2 diabetes [38] . Additional studies are needed to determine the actions of SeP on the enhanced angiogenesis in diabetic retinopathy or nephropathy.
Unlike phosphorylation of VEGFR2 and ERK1/2, VEGFinduced phosphorylation of Akt, p38 MAPK and protein kinase, AMP-activated, α1 catalytic subunit (AMPK) was unchanged by SeP in HUVECs (data not shown). Although the detailed molecular mechanism by which SeP selectively impairs VEGFR2/ERK pathway in HUVECs is still unknown, SeP might act on ERK-selective MAPK phosphatases [39] . In fact, some MAPK phosphatases are inactivated by intracellular oxidative stress [39] . However, SeP-induced selective impairment of VEGFR2/ERK pathway should be confirmed in other vascular endothelial cells.
All the culture media we used for HUVECs in this study contained 5.5 mmol/l glucose, which corresponds to fasting plasma glucose levels in people with normal glucose tolerance. However, we confirmed that SeP also attenuated VEGF signalling of HUVECs in the presence of 25 mmol/l glucose (data not shown). These results suggest that SeP induces VEGF resistance in HUVECs in both normoglycaemic and hyperglycaemic conditions. However, additional experiments are clearly needed to determine whether SeP sufficiently removes hyperglycaemia-induced chronic oxidative stress in vascular endothelial cells.
We have shown that serum levels of total selenium were unchanged in the mice injected with SEPP1 plasmid compared with the control animals ( Fig. 4c) , in spite of the significant elevation of serum SeP (Fig. 4b) . Selenium content in forms other than SeP might decrease in the serum of the SeP-transgenic mice compensatively [14, 40] . Because a recent report showed that SeP exerts antioxidative actions independently of selenium supply [41] , we speculate that the phenotype of the SeP-transgenic mice reflects the action of SeP itself, not the abnormal selenium distribution in mice.
Sepp1-heterozygous-knockout mice exhibited an increase in angiogenesis during hindlimb ischaemia without the induction of diabetes (Fig. 5) , suggesting that the hepatokine SeP plays a role in the regulation of systemic angiogenesis, irrespective of diabetes status. For example, lipopolysaccharideinduced acute inflammation was reported to downregulate the production of SeP in mice [42] . Angiogenesis promoted by suppressed production of SeP might be beneficial in inflammatory conditions. Further characterisation of Sepp1-deficient mice will provide insights into the involvement of SeP in the regulation of angiogenesis in normoglycaemic conditions. Serum levels of human SeP in the mice injected with human SEPP1 plasmid reached approximately 2.0 μg/ml (Fig. 4b ). This corresponds with the incremental change in serum level of SeP from that of people with normal glucose tolerance to that of people with type 2 diabetes in the Japanese population [15, 25] . This strongly suggests that the phenotype observed in the SeP-transgenic mice reflects the physiological actions of SeP.
One limitation of the present study is that we examined the action of SeP on endothelial cells only. Various types of cell participate in the angiogenic processes. Further studies are necessary to determine whether SeP exerts effects on other cell types such as the monocytes or endothelial progenitor cells.
Another limitation of the present study is that we carried out all the experiments of Sepp1-deficient mice without the induction of diabetes with a high-fat diet or streptozotocin. Hence, we did not investigate the contribution of SeP in the development of the dysregulated angiogenesis seen in diabetes in vivo. However, our data indicate that treatment with purified SeP directly inhibits angiogenesis in both vascular endothelial cells and mice under euglycaemic conditions. Combined with the previous reports showing the elevated production of SeP in type 2 diabetes [15, 16] , the current data suggest that overproduction of SeP contributes to the onset of impaired angiogenesis in type 2 diabetes. However, further studies in animals with diabetes are necessary to determine the degree of the contribution of SeP on the impaired angiogenesis observed in diabetes.
In summary, the present study indicates that the diabetesassociated hepatokine SeP impairs angiogenesis by reducing VEGF signal transduction in endothelial cells, and suggests that SeP may be a novel therapeutic target for treatment of VEGF resistance in people with type 2 diabetes.
